John F. Heerdink, Jr.’s Post

Thoughts on this? >> Ex-Pfizer drug reduces osteoarthritis pain in British biotech's phase 2 study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #biotech #pharmaceutical

Thoughts on this? >> Ex-Pfizer drug reduces osteoarthritis pain in British biotech's phase 2 study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #competitivemarketing

𝗡𝗮𝗻𝗼𝗹𝗶𝗽𝗼𝘀𝗼𝗺𝗲𝘀 𝗣𝗲𝗿𝗺𝗲𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗮 𝗠𝗶𝗰𝗿𝗼𝗳𝗹𝘂𝗶𝗱𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗮𝗰𝗿𝗼𝘀𝘀 𝗮 𝟯𝗗 𝗛𝘆𝗱𝗿𝗼𝗴𝗲𝗹 Nanoliposomes are nano-sized vesicles that can be used as drug delivery carriers with the ability to encapsulate both hydrophobic and hydrophilic compounds. Moreover, their lipid compositions facilitate their internalization by cells. However, the interaction between nanoliposomes and the membrane barrier of the human body is not well-known. If cellular tests and animal testing offer a solution, their lack of physiological relevance and ethical concerns make them unsuitable to properly mimic human body complexity. Microfluidics, which allows the environment of the human body to be imitated in a controlled way, can fulfil this role.  Read more in the article. #pharmaceutical #microfluids

Silo Pharma Launches SP-26 Study For Chronic Pain And Fibromyalgia. The company has announced the initiation of a pharmacokinetic (PK) and tolerability study. This study will be performed in collaboration with AmplifyBio, its contract research organization (CRO). The study aims to evaluate the pharmacokinetics of SP-26, a dissolvable ketamine-based injectable implant, in a minipig model. SP-26 is being developed as a self-administered, non-opioid treatment for chronic pain and fibromyalgia. Dive into the news via Pharma Now - Empowering Pharma Leadership: https://bit.ly/49MdNCI #Biopharma #ClinicalStudy

𝗡𝗼𝘃𝗲𝗹 𝗻𝗮𝗻𝗼-𝗶𝗻-𝗺𝗶𝗰𝗿𝗼 𝗳𝗮𝗯𝗿𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲 𝗼𝗳 𝗱𝗶𝗰𝗹𝗼𝗳𝗲𝗻𝗮𝗰 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗹𝗼𝗮𝗱𝗲𝗱 𝗺𝗶𝗰𝗿𝗼𝗻𝗲𝗲𝗱𝗹𝗲 𝗽𝗮𝘁𝗰𝗵𝗲𝘀 𝗳𝗼𝗿 𝗹𝗼𝗰𝗮𝗹𝗶𝘀𝗲𝗱 𝗮𝗻𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗱𝗿𝘂𝗴 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 by Mingshan Li, Lalitkumar Vora, PhD, Ke PENG, Akmal Hidayat B Sabri, Nuoya Qin, Marco Abbate, Alejandro J. Paredes, Helen McCarthy, Ryan Donnelly Diclofenac, a nonsteroidal anti-inflammatory drug, is commonly prescribed for managing osteoarthritis, rheumatoid arthritis, and post-surgical pain. However, oral administration of diclofenac often leads to adverse effects. This study introduces an innovative nano-in-micro approach to create diclofenac nanoparticle-loaded microneedle patches aimed at localised, sustained pain relief, circumventing the drawbacks of oral delivery. The nanoparticles were produced via wet-milling, achieving an average size of 200 nm, and then incorporated into microneedle patches. These patches showed improved skin penetration in ex vivo tests using Franz-cell setups compared to traditional diclofenac formulations. Read more in the article. #pharmaceutical #nanoparticles #microneedles

New Blog 📢: Ashley Rezak focuses on how #nasal drug delivery offers several advantages over traditional routes, making it increasingly prevalent among patients and healthcare providers alike. According to PharmaCircle, it is estimated that nasal products currently comprise approximately 20% of the preclinical prescription pipeline, versus only 7% of marketed products, demonstrating their growing popularity. Read the full blog now: https://lnkd.in/epBK98vb

Hello connections , view about ocular drug delivery system #snsdesignthinkers #snsinstitutions #snscollegeofpharmacy Topical administration for ocular therapeutics is ideal because of smaller doses required compared to the systemic use, its rapid onset of action and freedom from systemic toxicity Topically applied ocular drugs have to reach the inner parts of the eye and transcorneal penetration is believed to be the major route for drug absorption. Corneal absorption is much slower process than elimination. The specific aim of designing a therapeutic system is to achieve an optimal concentration of a drug at the active site for the appropriate duration. Ideal ophthalmic drug delivery must be able to sustain the drug release and to remain in the vicinity of front of the eye for prolong period of time. Consequently it is imperative to optimize ophthalmic drug delivery; one of the way to do so is by addition of polymers of various grades, development of in situ gel or colloidal suspension or using erodible or non erodible insert to prolong the pre corneal drug retention. This review focused on controlled and sustained drug delivery has become the standard in modern pharmaceutical design and several possible routes of drug delivery into the ocular tissues. 

🔍 Spotlight on the Ophthalmic Drugs Contract Manufacturing Market 👁️ The ophthalmic drug market is experiencing rapid growth, driven by the rising prevalence of eye diseases, increasing demand for advanced treatments, and the growing need for specialized manufacturing capabilities. As more pharmaceutical companies focus on innovative ophthalmic therapies, contract manufacturing organizations (CMOs) are playing a crucial role in meeting the demand for high-quality, cost-effective solutions. 𝐊𝐞𝐲 𝐝𝐫𝐢𝐯𝐞𝐫𝐬 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭: 🌟 𝐑𝐢𝐬𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐄𝐲𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: Conditions like glaucoma, diabetic retinopathy, macular degeneration, and dry eye disease are on the rise globally, increasing the need for novel ophthalmic drugs and therapies. 💡𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐎𝐩𝐡𝐭𝐡𝐚𝐥𝐦𝐢𝐜 𝐃𝐫𝐮𝐠 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬: Advances in biologics, gene therapies, and targeted drug delivery systems are pushing the need for specialized contract manufacturing services. 🔬𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐍𝐞𝐞𝐝𝐬: Ophthalmic drug production demands precision, sterile processing, and compliance with rigorous quality standards, which CMOs are well-equipped to handle. 📈 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡: The ophthalmic contract manufacturing market is expanding as pharmaceutical companies look for reliable partners to accelerate product development, improve efficiency, and scale production. The ophthalmic drugs contract manufacturing market is poised for continued growth, with CMOs serving as integral players in the development and commercialization of cutting-edge therapies that will improve eye health worldwide. 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐨𝐧 : https://lnkd.in/gzacXUbu #OphthalmicDrugs #ContractManufacturing #PharmaOutsourcing #Biopharma #EyeCare #HealthcareInnovation #PharmaceuticalManufacturing #CMO #Ophthalmology

𝗔𝘁𝗼𝗿𝘃𝗮𝘀𝘁𝗮𝘁𝗶𝗻-𝗟𝗼𝗮𝗱𝗲𝗱 𝗗𝗶𝘀𝘀𝗼𝗹𝘃𝗶𝗻𝗴 𝗠𝗶𝗰𝗿𝗼𝗮𝗿𝗿𝗮𝘆 𝗣𝗮𝘁𝗰𝗵𝗲𝘀 𝗳𝗼𝗿 𝗟𝗼𝗻𝗴-𝗔𝗰𝘁𝗶𝗻𝗴 𝗠𝗶𝗰𝗿𝗼𝗱𝗲𝗽𝗼𝘁 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆: 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻 𝗼𝗳 𝗡𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗮𝗻𝗱 𝗠𝗶𝗰𝗿𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗗𝗿𝘂𝗴 𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 by Yara Naser Lalitkumar Vora, PhD , Dr Ismaiel Tekko, B.Pharm, PhD in Drug Delivery , Ke PENG, Fabiana Volpe Zanutto, Brett Greer, Alejandro J. Paredes, Helen McCarthy, Ryan Donnelly The increasing popularity of prolonged-release dosage forms, owing to their ability to provide continuous drug release after administration, has significantly improved patient compliance and overall quality of life. However, achieving prolonged release beyond 24 h frequently requires the use of invasive methods, including injections or implants, which may prove challenging for people suffering from needle phobia. This study introduces atorvastatin (ATR) microparticles (MPs) or nanocrystal (NCs) dissolving microarray patches (D-MAPs) as a noninvasive alternative for intradermal drug delivery over a two-week period for the management of hyperlipidemia. #pharmaceutical #microneedles

𝗗𝗲𝘀𝗶𝗴𝗻 𝗼𝗳 𝗰𝗼𝗹𝗼𝗻-𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗱𝗿𝘂𝗴 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗼𝗳 𝗱𝗲𝘅𝗮𝗺𝗲𝘁𝗵𝗮𝘀𝗼𝗻𝗲: 𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘁𝗿𝗼 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘀𝗼𝗹𝗶𝗱 𝗱𝗶𝘀𝗽𝗲𝗿𝘀𝗶𝗼𝗻𝘀 Colon-targeted drug delivery continues to generate increasing attention for its prospects in treating inflammatory bowel disease (IBD). This study aimed to develop and evaluate colon-targeted solid dispersions of dexamethasone (DEX-SDs) in vitro to reduce its systemic exposure. This would ultimately improve the therapeutic efficacy of DEX while minimizing its adverse effects. Different DEX-SDs formulations were prepared utilizing Eudragit S100 (EU S100) and a combination of hydroxypropyl methyl cellulose (HPMC) and EU S100 to tune its drug release profile suitable for colonic delivery. The fabricated formulations were extensively characterized via Attenuated Total Reflectance – Fourier Transform Infrared Spectroscopy (ATR-FTIR), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and polarized light microscopy (PLM).